Table of Contents

Dupixent (dupilumab) has become a breakthrough option for several inflammatory conditions by targeting inflammation at its source. But like all medications, it can also bring unwanted effects that some users don’t expect.

These reactions are usually mild, but for some people, they can interrupt progress or cause enough discomfort to question whether continuing Dupixent is worth it.

This article helps you understand the side effects of Dupixent and learn which reactions are common or rare and when it’s important to contact your doctor. Knowing what to expect can help you use Dupixent safely and confidently as part of your ongoing care plan.

Key Takeaways

  • Most side effects are mild and temporary, including injection site reactions, minor herpes infections, or transient increases in eosinophils that usually resolve without stopping treatment.
  • Eye-related side effects from Dupixent are the most distinct concern, as its mechanism can disrupt tear balance and eye surface health, leading to dryness or inflammation that often improves with care.
  • Muscle and joint pain can occur in some users, but these symptoms are uncommon, and most people continue treatment successfully once discomfort is managed.
  • Dupixent does not significantly increase infection risks, and studies show lower rates of severe or body-wide infections compared with older immunosuppressing drugs.
  • Cancer risk remains unproven, with current evidence showing no link between Dupixent and higher malignancy rates in long-term users.

How does Dupixent work in the body?

Dupilumab, the active ingredient of Dupixent, is a lab-made antibody that targets a protein called the interleukin-4 receptor alpha. By attaching to this receptor, it blocks signals from two immune messengers, IL-4 and IL-13, that are responsible for allergic and inflammatory reactions.

When these signals are blocked, inflammation in the body calms down. As a result, symptoms of conditions like eczema, asthma, nasal polyps, and eosinophilic esophagitis improve. Large clinical trials comparing Dupixent with placebo have confirmed these benefits, and its safety record is similar across different diseases and age groups.

However, the way Dupixent works to improve these symptoms can also explain why certain side effects happen.

Dupixent

The Most Common Side Effects of Dupixent

Across different conditions, some side effects occur repeatedly, though their frequency varies depending on the disease being treated. The most common side effects of Dupixent injections include:

Injection site reactions

Pain, redness, swelling, or itching at the injection site are common with Dupixent. Such reactions were most often seen after the first, or loading, dose. These reactions are usually mild and go away within a short time.

In clinical trials, the rate of injection site reactions was highest among patients with eosinophilic esophagitis, affecting about 38% of those treated. But these reactions were not seen in patients treated for prurigo nodularis or bullous pemphigoid.

Eye side effects

Close up of one annoyed red blood eye of male

Dupixent blocks two immune signals, interleukin-4 (IL-4) and interleukin-13 (IL-13), that normally help protect and balance the surface of the eyes.

In particular, IL-13 helps maintain goblet cells, which produce a protective mucus that keeps the eyes moist and the tear film stable. Without enough IL-13, the number of goblet cells drops sharply, mucus production decreases, and the eyes become dry and irritated.

Studies of tissue samples from dupilumab users show that goblet cell counts can fall from about 32 cells/mm² to just 3, along with increased inflammation from immune cells such as T cells and eosinophils.

Some studies also link dupilumab-related eye issues to an overgrowth of Demodex mites, which are tiny organisms that normally live harmlessly in the eyelash area. Blocking IL-4 and IL-13 may weaken local immune defenses, allowing these mites to multiply.

Excess Demodex can trigger eyelid inflammation (blepharitis) and oil gland blockage (meibomian gland dysfunction), causing a rosacea-like eye condition.

Dupixent can cause several eye-related side effects, including:

  • Conjunctivitis – This is the most common Dupixent eye side effect, especially in people with atopic dermatitis. In clinical trials, conjunctivitis occurred in up to 10% of patients. Symptoms usually start within the first few weeks of treatment and include:
      • redness
      • itching
      • tearing
      • discharge
    Most cases are mild to moderate and improve without stopping Dupixent. Severe or chronic cases may need eye drops containing corticosteroids or regular monitoring by an eye specialist.
  • Blepharitis – Blepharitis, or eyelid inflammation, is also seen with Dupixent use, though the exact rate is uncertain. In one study, about 31% of patients developed new eyelid irritation after starting treatment. Symptoms include red, swollen, or itchy eyelids, a burning sensation, and dry or watery eyes. There are two types:
      • Anterior blepharitis – affects the base of the lashes, often linked to bacteria or Demodex mites.
      • Posterior blepharitis (meibomitis) – affects the oil glands inside the eyelids, leading to unstable tears and dryness.
    Both forms can occur together and cause significant discomfort. Regular eyelid cleaning, warm compresses, and anti-inflammatory eye drops may help control symptoms.
  • Keratitis – Inflammation on the surface of the eye can also cause keratitis, related to tear film instability and goblet cell loss caused by Dupixent. Most reported cases are superficial keratitis, showing redness, burning, light sensitivity, and blurry vision. Treatment usually includes lubricating or anti-inflammatory drops and sometimes temporary discontinuation of Dupixent in severe cases.
  • Other rare complications – A few isolated cases describe:
      • corneal ulcers
      • punctal stenosis or the narrowing of the tear duct openings
      • cicatricial conjunctivitis
      • periocular dermatitis
      • uveitis (inflammation inside the eye)
    Other rare findings include stem cell damage on the cornea leading to vision changes, which may require advanced treatments like serum eye drops or immunomodulatory therapy. Stopping the medication usually improves symptoms.

Note: Not everyone will experience these side effects. Experts suggest that patients who are older, have a history of eye inflammation, or have more severe eczema are much more likely to experience eye side effects from Dupixent.

Mild herpes simplex infections

Herpes simplex infections are caused by the herpes simplex virus (HSV), which comes in two main types:

    • HSV-1 – usually causes cold sores around the mouth or lips, but it can also affect the face, eyes, or genitals.
    • HSV-2 – most often causes genital herpes, but it can also appear on other body parts.

In clinical studies, people using Dupixent had lower rates of serious herpes infections such as eczema herpeticum and shingles (herpes zoster). However, mild herpes simplex infections, like cold sores or small recurrent blisters, were common.

According to real-world data, Dupixent users had fewer infections overall compared with people taking methotrexate or cyclosporine. Results showed:

    • Herpes infections: 35-40% lower risk
    • Other skin infections: 45-55% lower risk
    • Serious body-wide infections: about 50-60% lower risk

Compared to cyclosporine and methotrexate, Dupixent users were less likely to get infections such as:

    • pneumonia
    • urinary tract infections
    • sinusitis
    • ear infections
    • herpes
    • hepatitis B or C reactivation
    • flu
    • fungal or parasitic diseases
    • sepsis
    • meningitis
    • encephalitis
    • bone infections
    • tuberculosis

Importantly, Dupixent did not increase the risk of eczema herpeticum, which is a severe herpes infection sometimes seen in people with atopic dermatitis.

If you’re not severely immune-compromised, it’s very unlikely that you’ll experience repeated shingles outbreaks. A small recurring sore, especially around your lips or buttocks, is much more likely to be herpes simplex rather than shingles. Any herpes flare-ups can typically be managed with an antiviral medicine such as valacyclovir.

Vaccination Reminder for Dupixent Users

Staying up to date with your vaccines is an important part of safe treatment. Try to complete all recommended vaccinations before starting Dupixent treatment, following current immunization guidelines.

Avoid live vaccines (such as MMR, varicella, or yellow fever) while receiving Dupixent. It’s unknown whether getting a live vaccine during treatment could affect the safety or effectiveness of the vaccine.

There’s limited data on giving non-live vaccines (like flu or COVID-19 vaccines) at the same time as Dupixent, but current evidence suggests they are generally safe to use.

Always talk to your healthcare provider about vaccine timing before and during treatment.

Eosinophilia

Eosinophilia means having too many eosinophils, a type of white blood cell, in your blood or tissues. Eosinophils normally help your body fight infections and respond to allergies. But when their numbers get too high, they can cause inflammation and damage in different organs.

A temporary rise in eosinophils is common with Dupixent, but it’s usually harmless and goes away on its own.

In studies involving people with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and eczema, eosinophil counts usually went up by week 4-16, then returned to normal or lower levels by week 24. People with eosinophilic esophagitis did not show any increase in eosinophils.

Only 7 out of 4,666 patients developed symptoms from this rise, including 6 cases of a rare condition called eosinophilic granulomatosis with polyangiitis, and these occurred only in people with asthma or nasal polyps.

Keep an eye out for any of these warning signs:

    • fever or cough
    • chest pain or shortness of breath
    • new rash, numbness, or tingling in your arms or legs

If you notice any of these symptoms, contact your doctor right away. They may pause your Dupixent treatment while checking for other causes. Most people never experience these problems, but staying aware helps keep your treatment safe.

Less Common Dupixent Side Effects

Some side effects of Dupixent occur less frequently but are still important to recognize. These reactions include:

Musculoskeletal symptoms

Neck And Back Pain

Musculoskeletal symptoms have been reported in some patients using Dupixent, including:

    • arthralgia (joint pain)
    • myalgia (muscle pain)
    • back pain

Postmarketing reports have also described cases of new-onset psoriatic arthritis.

Doctors at one medical center reviewed the records of 470 patients with atopic dermatitis who started Dupixent between October 2018 and February 2021. Out of those, 36 patients were referred to a rheumatologist for new pain or swelling. After detailed exams and imaging tests like ultrasound or MRI, 26 patients were confirmed to have inflammatory musculoskeletal problems, mainly:

    • Enthesitis – inflammation where tendons or ligaments attach to bone
    • Arthritis – joint inflammation
    • Tenosynovitis – inflammation of the tendon sheaths

There were no clear warning signs to predict who would develop these side effects.

Most patients (16) had mild symptoms, 6 had moderate, and 4 had severe pain. Despite the joint issues, all patients’ skin improved greatly with Dupixent.

In one case report, a 68-year-old male patient developed severe muscle pain and joint pain after his third Dupixent shot. He described constant pain and spasms in both thighs, along with aching in his hips and knees that interfered with sleep and daily activities.

He reported no new exercise routines, injuries, or trauma. While he appreciated how well Dupixent had cleared his eczema, the muscle and joint pain greatly affected his quality of life.

Mouth and throat symptoms

Some patients have experienced toothache or soreness in the mouth or throat, especially in those using Dupixent for CRSwNP, asthma, and COPD.

In clinical trials, toothache occurred in about 1% of CRSwNP patients and 2.1% of COPD patients. Oropharyngeal pain or pain felt in the back of the mouth, tonsils, soft palate, or upper throat was reported in about 2% of asthma patients.

These side effects may occur because Dupixent targets the same immune pathways involved in these airway conditions.

Upper respiratory tract infections

Many people on biologic drugs like Dupixent report upper respiratory tract infections (URTIs) as side effects, such as:

    • nasopharyngitis (common cold)
    • sinus infections
    • sore throats

Those with asthma, nasal polyps, or eczema are more likely to get URTIs because of chronic inflammation and mucus buildup.

Across studies, rates ranged from 0.35% to 41.5% among patients using biologics or JAK inhibitors (abrocitinib, upadacitinib), and 0% to 40% among those on placebo. On average, 9.7% of people on these drugs developed a URTI, compared with 8% on placebo.

Head and nerve-related symptoms

Dupixent may sometimes be associated with nervous system-related symptoms, such as:

    • headache
    • dizziness
    • insomnia

However, research suggests these effects are rarely caused by the drug itself. They’re more likely linked to the underlying conditions Dupixent treats, such as asthma or nasal polyps, or to the body adjusting during the early phase of treatment.

In fact, studies show Dupixent may actually improve sleep quality rather than worsen it. One analysis found a 22% lower risk of sleep problems in people taking Dupixent compared with those using older immunosuppressants like steroids, methotrexate, cyclosporine, or azathioprine.

In another study involving patients with severe asthma, 46-65% of Dupixent users reported better sleep after 24 weeks, compared with 27-48% on placebo. These improvements lasted up to two years in those who continued treatment, and patients who switched from placebo later experienced similar benefits.

Gastrointestinal effects

In clinical trials, gastritis was reported in about 2% of people taking Dupixent for chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. Meanwhile, diarrhea occurred in around 3% of patients treated for prurigo nodularis and 3.7% of those treated for COPD.

The Long-Term Side Effects of Dupixent

Certain events have led doctors to keep a closer watch during treatment. These include:

Malignancy risk

A 2023 case series described four patients who developed cancer while on Dupixent. One patient was diagnosed with prostate cancer two months after starting treatment, but given the patient’s age (61 years) and the short time between treatment and diagnosis, researchers considered it unlikely that Dupixent caused the cancer. Three others had skin cancers.

However, the link between Dupixent and cancer development remains unclear. Reports from other studies also show that patients who had previous or existing cancers did not experience cancer recurrence or relapse while on Dupixent.

An allergy and immunology academy review also found no sign of higher cancer rates in people taking medications that block type 2 inflammation, such as Dupixent.

Immunogenicity

Some people can develop antibodies against dupilumab over time.

A 2024 study that looked at both adults and children found that antibodies against dupilumab are uncommon and usually temporary. For most patients, they do not affect how well the drug works or its safety. Only a very small number of people with high antibody levels showed reduced benefit, which often improved with ongoing treatment.

These findings show that Dupixent remains effective and stable for long-term use in most patients.

Long-Term Safety and Tolerability of Dupixent

Many long-term studies and real-world reports have now followed people taking Dupixent for 2-5 years or more. The results have been consistent.

The same side effects that appear early in treatment are usually the ones seen later, and no new safety concerns have emerged over time. Overall, Dupixent continues to be well-tolerated, and only a small number of people stop treatment because of side effects.

  • Atopic dermatitis up to five years. Most patients maintained significant skin improvement and quality of life benefits without new or worsening side effects. The most common mild side effects were:
      • common cold
      • mild eczema flare-ups
      • upper respiratory infections
      • conjunctivitis
      • headache
      • cold sores (oral herpes)
      • mild redness or itching at the injection site
    These side effects remained stable or decreased over time.
  • Asthma up to three years. Dupixent remained safe and well-tolerated for up to an additional 3 years in people with moderate to severe asthma. About 55% of patients experienced at least one side effect, but most were mild or moderate. Common issues included mild infections, injection site reactions, or temporary symptoms similar to those seen in earlier trials.
  • Children with asthma and dermatitis. Dupixent remained safe and well-tolerated in children aged 6-11 years with moderate to severe asthma. About 64% of children (232 out of 365) had at least one side effect, which is similar to the rates seen in the earlier trial. The most common mild side effects were:
      • common cold
      • sore throat
      • upper respiratory tract infections

Recap

Common side effects of Dupixent include mild injection site reactions and eye problems like dryness, redness, or conjunctivitis. Less common effects include joint or muscle pain, mild herpes infections, and temporary increases in eosinophil counts. Long-term studies show Dupixent continues to provide lasting benefits with a strong safety record when used under medical supervision.

Contact your doctor right away if you experience persistent eye discomfort, worsening skin inflammation, signs of infection, or any unusual allergic reactions such as swelling, shortness of breath, or dizziness while on Dupixent. Prompt medical attention helps ensure your treatment remains safe and effective.

Related Articles

Frequently Asked Questions

Dupixent is prescribed for chronic inflammatory conditions linked to an overactive immune response. It treats moderate to severe eczema (atopic dermatitis), asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, and bullous pemphigoid. In all these conditions, Dupixent helps by blocking two inflammatory pathways, IL-4 and IL-13, reducing itching, swelling, and airway inflammation.

There are no withdrawal symptoms after stopping Dupixent, but your condition may gradually return. For eczema, this can mean worsening itching and flare-ups within weeks or months. For asthma or nasal polyps, breathing symptoms may slowly reappear as inflammation builds up again. Doctors sometimes taper off Dupixent or switch to other therapies to prevent rebound symptoms.

People using Dupixent for eczema may experience injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infections, dry eye, and eosinophilia.

For asthma, Dupixent’s most reported side effects are injection site reactions, oropharyngeal pain, and eosinophilia.

Common effects in people using Dupixent for nasal polyps include injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

Allergic reactions to Dupixent are uncommon but possible. Symptoms can include rash, facial or throat swelling, dizziness, or trouble breathing. If signs of an allergic response appear, treatment should be stopped and medical care sought immediately.

Sources

Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., Chao, J., Staudinger, H., Pirozzi, G., Antoni, C., Amin, N., Ruddy, M., Akinlade, B., Graham, N. M. H., Stahl, N., . . . Teper, A. (2018). Efficacy and safety of dupilumab in Glucocorticoid-Dependent severe asthma. New England Journal of Medicine, 378(26), 2475–2485. https://doi.org/10.1056/nejmoa1804093

Dellon, E. S., Rothenberg, M. E., Collins, M. H., Hirano, I., Chehade, M., Bredenoord, A. J., Lucendo, A. J., Spergel, J. M., Aceves, S., Sun, X., Kosloski, M. P., Kamal, M. A., Hamilton, J. D., Beazley, B., McCann, E., Patel, K., Mannent, L. P., Laws, E., Akinlade, B., . . . Shabbir, A. (2022). Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. New England Journal of Medicine, 387(25), 2317–2330. https://doi.org/10.1056/nejmoa2205982

Bakker, D., Ariens, L., Luijk, C., Schaft, J., Thijs, J., Schuttelaar, M., Wijk, F., Knol, E., Balak, D., Dijk, & Bruin?Weller. (2018). Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. British Journal of Dermatology, 180(5), 1248–1249. https://doi.org/10.1111/bjd.17538

Boscia, G., Spataro, F., Desantis, V., Solimando, A. G., Vacca, A., Ria, R., & Savastano, A. (2025). Ocular side effects of dupilumab: A Comprehensive Overview of the literature. Journal of Clinical Medicine, 14(7), 2487. https://doi.org/10.3390/jcm14072487

Shim, S., Kim, J. S., Yee, J., & Gwak, H. S. (2024). A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1425550

Dupilumab and recurrent localized herpes simplex. (n.d.). https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2024/herpe

Kridin, K., Abdelghaffar, M., Bieber, K., Thaci, D., & Ludwig, R. J. (2025). The real?world, long?term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20724

Wechsler, M. E., Klion, A. D., Paggiaro, P., Nair, P., Staumont-Salle, D., Radwan, A., Johnson, R. R., Kapoor, U., Khokhar, F. A., Daizadeh, N., Chen, Z., Laws, E., Ortiz, B., Jacob-Nara, J. A., Mannent, L. P., Rowe, P. J., & Deniz, Y. (2022). Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. The Journal of Allergy and Clinical Immunology in Practice, 10(10), 2695–2709. https://doi.org/10.1016/j.jaip.2022.05.019

Hughes, C. D., Nathan, J., Mathew, L., Pink, A. E., Woolf, R. T., Smith, C., Menon, B., & Kirkham, B. (2023). Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an interleukin?4/13 inhibitor. Arthritis & Rheumatology, 75(10), 1793–1797. https://doi.org/10.1002/art.42558

Cochran, B. L., Raymond-Lezman, J. R., Coican, A., Sagasser, N., Patel, R., Batrous, S., & Greenfield, M. F. (2024). The rare adverse effect of myalgia after dupilumab biologic therapy for refractory atopic dermatitis. Cureus. https://doi.org/10.7759/cureus.60701

Alraddadi, R., Kalantan, M., Aljefri, Y., Maaddawi, H., Alsamadani, A., Kadasa, A., Softah, A., Tabbakh, B., Alturkistani, R., & Jfri, A. (2025). Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1550640

Lin, T., Fan, Y., Fan, K., Juan, C., Chen, Y., & Wu, C. (2024). Dupilumab reduces psychiatric and sleep disorder risk in atopic dermatitis: a population-based cohort study. Annals of Allergy Asthma & Immunology, 134(3), 333-340.e6. https://doi.org/10.1016/j.anai.2024.11.016

Sher, L. D., Passalacqua, G., Taillé, C., Cohn, L., Daizadeh, N., Pandit-Abid, N., Soler, X., Khodzhayev, A., Jacob-Nara, J. A., Deniz, Y., Rowe, P. J., Nag, A., & Zhang, Y. (2022). The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma. Annals of Allergy Asthma & Immunology, 130(3), 298–304. https://doi.org/10.1016/j.anai.2022.12.002

Alaimo, K. L., Ramcharan, D. N., & Shaw, O. G. (2023). Managing a Patient Presenting With Chest Pain and Gastrointestinal Complaints Using Dupilumab. Cureus, 15(10), e46478. https://doi.org/10.7759/cureus.46478

Beck, L. A., Bissonnette, R., Deleuran, M., Nakahara, T., Galus, R., Coleman, A., Gherardi, G., Xiao, J., Dingman, R., Xu, C., Avetisova, E., Dubost-Brama, A., & Shabbir, A. (2024). Dupilumab in adults with moderate to severe atopic dermatitis. JAMA Dermatology, 160(8), 805. https://doi.org/10.1001/jamadermatol.2024.1536

Maspero, J. F., Peters, A. T., Chapman, K. R., Domingo, C., Stewart, J., Hardin, M., Maroni, J., Tawo, K., Khokhar, F. A., Mortensen, E., Laws, E., Radwan, A., Jacob-Nara, J. A., Deniz, Y., & Rowe, P. J. (2023). Long-Term safety of dupilumab in patients with Moderate-to-Severe asthma: TRAVERSE Continuation study. The Journal of Allergy and Clinical Immunology in Practice, 12(4), 991-997.e6. https://doi.org/10.1016/j.jaip.2023.12.043

Bacharier, L. B., Maspero, J. F., Katelaris, C. H., Fiocchi, A. G., Gagnon, R., De Mir, I., Guilbert, T. W., Jackson, D. J., Staudinger, H. W., Laws, E., Mannent, L. P., Akinlade, B., Maloney, J., Tawo, K., Khokhar, F. A., Li, N., Hardin, M., Abdulai, R. M., Lederer, D. J., . . . Robinson, L. B. (2023). Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. The Lancet Respiratory Medicine, 12(1), 45–54. https://doi.org/10.1016/s2213-2600(23)00303-x

Gargiulo, L., Vignoli, C. A., Cortese, A., Ibba, L., Costanzo, A., & Narcisi, A. (2023). Real-Life Safety and Effectiveness of Dupilumab in Patients with Concomitant Malignancies: a Case Series. Dermatology practical & conceptual, 13(3), e2023143. https://doi.org/10.5826/dpc.1303a143

Dupilumab therapy with metastatic cancer. (n.d.). https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2022/metastatic

Kamal, M. A., Kosloski, M. P., Lai, C., Partridge, M. A., Rajadhyaksha, M., Kanamaluru, V., Bansal, A., Shabbir, A., Shumel, B., Ardeleanu, M., Richards, S. M., Yan, H., Xu, C. R., Rodríguez-Marco, A., Xiao, J., Khokhar, F. A., Gherardi, G., Babilonia, E., Maloney, J., . . . DiCioccio, A. T. (2024). Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1466372